This is a working overview of ghrelin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-31. Anything still debated is marked as such rather than presented as settled.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Bicalutamide is used as an antiandrogen in feminizing hormone therapy for transgender women and as a puberty blocker in adolescent transgender girls. It can be used in transgender females both in combination with an estrogen and alone. The medication directly blocks the effects of androgens like testosterone and dihydrotestosterone in the body, and, when used by itself, also induces a significant increase in estradiol levels. As a result, bicalutamide causes demasculinization, and can additionally promote feminization, even without concomitant use of estrogen. This is analogous to what occurs in women with a defective AR due to complete androgen insensitivity syndrome. Demasculinizing and feminizing effects of bicalutamide in those assigned male at birth include breast development, reduced male-pattern hair, decreased muscle mass, feminine changes in fat distribution, decreased sex drive, and reduced spontaneous erections. Dosages of bicalutamide of 25 to 50 mg/day have been used and recommended in transgender females. Lower doses may also be effective. Unlike various other antiandrogens, bicalutamide when used as a monotherapy significantly increases testosterone and estradiol levels in individuals assigned male at birth, and hence can have indirect estrogenic effects in transgender women. This is desirable in transgender women, as it can help promote feminization.
Another method was to use range-only measurements from multiple CH stations to produce fixes on individual targets, the "Chapman method". To aid this task, a second display would be installed that would be fed the Y-axis signal from a distant CH station over telephone lines. This way the operator could directly compare the two signals, eliminating the delays if this information was transmitted by voice. This system was never required.
Culture in German states has been shaped by major intellectual and popular currents in Europe, both religious and secular, and German scientists, writers and philosophers have played a significant role in the development of Western thought. Global opinion polls from the BBC revealed that Germany is recognised for having the most positive influence in the world in 2013 and 2014. Germany is well known for such folk festivals as the Oktoberfest and Christmas customs, which include Advent wreaths, Christmas pageants, Christmas trees, Stollen cakes, and other practices. As of 2025, UNESCO inscribed 55 properties in Germany on the World Heritage List. There are a number of public holidays in Germany determined by each state; 3 October has been a national day of Germany since 1990, celebrated as the Tag der Deutschen Einheit (German Unity Day).
Sources: en.wikipedia.org
FLAG-tag, or FLAG octapeptide, or FLAG epitope, is a peptide protein tag that can be added to a protein using recombinant DNA technology, having the sequence DYKDDDDK (where D=aspartic acid, Y=tyrosine, and K=lysine). It is one of the most specific tags and it is an artificial antigen to which specific, high affinity monoclonal antibodies have been developed and hence can be used for protein purification by affinity chromatography and also can be used for locating proteins within living cells. FLAG-tag has been used to separate recombinant, overexpressed protein from wild-type protein expressed by the host organism. FLAG-tag can also be used in the isolation of protein complexes with multiple subunits, because FLAG-tag's mild purification procedure tends not to disrupt such complexes. FLAG-tag-based purification has been used to obtain proteins of sufficient purity and quality to carry out 3D structure determination by x-ray crystallography. A FLAG-tag can be used in many different assays that require recognition by an antibody. If there is no antibody against a given protein, adding a FLAG-tag to a protein allows the protein to be studied with an antibody against the FLAG-tag sequence. Examples are cellular localization studies by immunofluorescence, immunoprecipitation or detection by SDS PAGE protein electrophoresis and Western blotting. The peptide sequence of the FLAG-tag from the N-terminus to the C-terminus is: DYKDDDDK (1012 Da).
Convergent evolution—the repeated evolution of similar traits in multiple lineages which all ancestrally lack the trait—is rife in nature, as illustrated by the examples below. The ultimate cause of convergence is usually a similar evolutionary biome, as similar environments will select for similar traits in any species occupying the same ecological niche, even if those species are only distantly related. In the case of cryptic species, it can create species which are only distinguishable by analysing their genetics. Distantly related organisms often develop analogous structures by adapting to similar environments.
The Scottish Government backs plans to bar dual mandates – MSPs who also sit as MPs or members of the House of Lords – from sitting at Holyrood after the 2026 Scottish Parliament election. 11 December – The Scottish Government announces that Scotland will follow the UK's permanent ban on the use of puberty blockers for under-18s questioning their gender. 12 December – Catholic priest Father Daniel Doherty is sentenced to 16 months in prison after sexually assaulting a sleeping man on a train to Edinburgh. 13 December – The Glasgow South Western Line is closed between Carlisle and Gretna after a HGV crashes off the A74(M) motorway onto the railway line near Gretna; the driver is arrested and charged over the incident. 14 December – Seven people are taken to hospital for treatment, with one man in a critical condition, after the roof of a double-decker bus is torn off when it collides with a railway bridge in Glasgow City Centre after taking a wrong turn. 15 December – Violence and disorder breaks out in Glasgow city centre ahead of the Scottish League Cup final between Celtic and Rangers at Hampden Park. An IT issue forces flights at Edinburgh Airport to be suspended for several hours. 17 December – MSPs vote unanimously in favour of plans to ban dual mandates. Following an external review into the use of messaging services, Deputy First Minister Kate Forbes announces that Scottish Government ministers and staff will be banned from using WhatsApp for official business.
On 23 January 2024, Tristan Thompson was suspended for 25 games by the NBA for testing positive for ibutamoren and LGD-4033. On 12 March 2024, curler Briane Harris was provisionally suspended for up to four years after testing positive for LGD-4033. She denies this after being tested by doping control officers on Jan. 24 and notified of her positive test on Feb. 15. A second sample, called the B sample, also confirmed the positive test. She appealed the ban to the Court of Arbitration for Sport (CAS), arguing she was unknowingly exposed to it through bodily contact. CAS ruled that "Harris has established that she bears No Fault or Negligence for the anti-doping rule violation. No period of Ineligibility is imposed."
Sources: en.wikipedia.org
== Treatment == Currently, there are no treatments for any of the congenital myopathies. Depending on the severity, there are different therapies available to help alleviate any pain and aid patients in performing varying activities. For example, many congenital myopathy patients are involved in physical or occupational therapy in an attempt to strengthen their skeletal muscles. Orthopedic surgery is usually necessary to correct skeletal deformities secondary to muscle weakness, such as scoliosis. Survival is typically determined by the level of respiratory muscle insufficiency.
==== 2900–2999 ==== Farm and Conservation Grant (Amendment) Regulations 1993 (S.I. 1993/2900) Farm and Conservation Grant (Variation) Scheme 1993 (S.I. 1993/2901) Medicines (Pharmacies) (Applications for Registration and Fees) Amendment Regulations 1993 (S.I. 1993/2902) Motor Vehicles (Type Approval and Approval Marks) (Fees) (Amendment) Regulations 1993 (S.I. 1993/2903) Occupational Pensions (Revaluation) Order 1993 (S.I. 1993/2904) Family Provision (Intestate Succession) Order 1993 (S.I. 1993/2906) Western Isles Islands Council (Brevig) Harbour Empowerment Order 1993 (S.I. 1993/2908) Transport Act 1985 (Modifications in Schedule 4 to the Transport Act 1968) (Further Modification) (Amendment) Order 1993 (S.I. 1993/2909) Education (Mandatory Awards) (No. 2) Regulations 1993 (S.I. 1993/2914) Education (Student Loans) (No.2) Regulations 1993 (S.I. 1993/2915) Forth Ports Authority (Dissolution) Order 1993 (S.I. 1993/2916) A43 Trunk Road (Weldon Bypass) Order 1993 (S.I. 1993/2917) A43 Trunk Road (Stamford Road, Northamptonshire) (Detrunking) Order 1993 (S.I. 1993/2918) Firearms (Amendment) Act 1988 (Firearms Consultative Committee) Order 1993 (S.I. 1993/2919) Bovine Embryo Collection and Transfer (Fees) Regulations 1993 (S.I. 1993/2920) Bovine Embryo Collection and Transfer Regulations 1993 (S.I. 1993/2921) Consumer Credit (Exempt Agreements) (Amendment) (No. 2) Order 1993 (S.I. 1993/2922) Imitation Dummies (Safety) Regulations 1993 (S.I. 1993/2923) Hill Livestock (Compensatory Allowances) (Amendment) (No. 2) Regulations 1993 (S.I.
The reduction and subsequent reoxidation of vitamin K coupled with carboxylation of Glu is called the vitamin K cycle. Humans are rarely deficient in vitamin K because, in part, vitamin K2 is continuously recycled in cells. Warfarin and other 4-hydroxycoumarins block the action of VKOR. This results in decreased concentrations of vitamin K and vitamin K hydroquinone in tissues, such that the carboxylation reaction catalyzed by the glutamyl carboxylase is inefficient. This results in the production of clotting factors with inadequate Gla. Without Gla on the amino termini of these factors, they no longer bind stably to the blood vessel endothelium and cannot activate clotting to allow formation of a clot during tissue injury. As it is impossible to predict what dose of warfarin will give the desired degree of clotting suppression, warfarin treatment must be carefully monitored to avoid underdose and overdose.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.